All topics
Functional ingredient atlas
A name alone does not establish equivalence to a studied material. Source, chemical form, branded preparation, strain, processing, active constituents and dose may matter. Candidate ingredients are not an approved FD1 formula.
In-depth articles
All articles →A map of related concepts; see the entries and sources for detail.
Reference entries
Omega-3: EPA/DHA, not just fish-oil massProject inference
ALA, EPA and DHA differ. A 1,000 mg fish-oil label is not 1,000 mg EPA+DHA; source, actual content and purpose matter.
PHGG: one specific fibre optionProject inference
Partially hydrolyzed guar gum has specific human evidence. A 2016 IBS trial using 6 g/day improved some bloating measures, not all symptoms or quality of life.
Polyphenols & plant extractsProject inference
Plant foods contain diverse bioactives. Evidence for whole foods does not automatically transfer to concentrated extracts or small “superfood” blends.
CoQ10: biological role versus supplement benefitProject inference
CoQ10 occurs naturally in the body. Evidence varies by indication; its energy-related role does not prove more energy in all healthy users.
Taurine: neither caffeine nor proven longevity therapyProject inference
The 2026 taurine+B trial found specific task signals; it does not establish longevity or sustained everyday energy from taurine alone.
Urolithin A: direct supplementation differs from food metabolismProject inference
UA is studied in mitophagy. Direct supplementation differs from eating precursor foods. Purified UA is often called a postbiotic, but does not meet ISAPP’s strict preparation-based definition.
Ergothioneine, EGTProject inference
A diet-derived antioxidant. A 2025 trial in 147 adults did not establish between-group benefit on the primary memory endpoint; blood increases do not prove cognition gains.
Saffron: evidence is preparation-specificProject inference
The 2026 trial used Affron at 28 mg/day in women of specific ages. Culinary saffron, other extracts and all-adult products cannot automatically inherit the result.
“Adaptogen” is not a uniform clinical effectProject inference
Rhodiola and ashwagandha are different plants. Some ashwagandha preparations have stress or insomnia signals with safety limits; reliable rhodiola evidence is insufficient.
Digestive enzymes: avoid borrowing treatment evidenceProject inference
Prescription pancreatic enzymes treat diagnosed insufficiency. This does not establish need for enzyme blends in all healthy adults; enzyme-activity units matter.
Creatine and the sports-nutrition boundaryProject inference
Exercise performance is an important creatine research context. FD1 is not currently a sports product; evidence in another context does not mandate inclusion.
C15:0 is not automatically a new essential fatty acidProject inference
The 2026 mouse study is worth tracking but does not establish human essentiality, deficiency criteria or a general-adult supplement dose.
Extracts and marker compounds
A plant material, total extract mass, standardized marker mass and the preparation studied in humans are distinct. Obtain specifications that can be checked.
Why the studied material matters
Changes in strain, extraction, specifications or carrier may affect comparability with a studied material. A shared commercial name does not automatically establish equivalence.